Search research articles
Contact Us
Filters
Showing results (331-340 of 436) with videos related to
Page
of 44
Sort By:
NEJM Evidence
|
May 28, 2024
Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes
Tapan M Kadia, Meixian Huang, Naveen Pemmaraju, et al.
The Lancet. Oncology
|
January 21, 2018
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
Hagop Kantarjian, Farhad Ravandi, Nicholas J Short, et al.
Cancer
|
March 4, 2020
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors
Betül Oran, Guillermo Garcia-Manero, Rima M Saliba, et al.
Blood Advances
|
April 7, 2020
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens
Curtis A Lachowiez, Sanam Loghavi, Tapan M Kadia, et al.
The Lancet. Haematology
|
August 18, 2018
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial
Tapan M Kadia, Jorge Cortes, Farhad Ravandi, et al.
Haematologica
|
May 2, 2024
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse
Alex Bataller, Hagop Kantarjian, Alexandre Bazinet, et al.
American Journal of Hematology
|
November 15, 2017
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms
Rita Assi, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
American Journal of Hematology
|
September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission
Nicholas J Short, Walid Macaron, Tapan Kadia, et al.
Blood Cancer Journal
|
May 2, 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML
Musa Yilmaz, Hagop Kantarjian, Nicholas J Short, et al.
The Lancet. Haematology
|
April 28, 2022
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Page
of 44
Search research articles
Search
Showing results (331-340 of 436) with videos related to
Sort By:
Page
of 44
NEJM Evidence
|
May 28, 2024
Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes
Tapan M Kadia, Meixian Huang, Naveen Pemmaraju, et al.
The Lancet. Oncology
|
January 21, 2018
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
Hagop Kantarjian, Farhad Ravandi, Nicholas J Short, et al.
Cancer
|
March 4, 2020
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors
Betül Oran, Guillermo Garcia-Manero, Rima M Saliba, et al.
Blood Advances
|
April 7, 2020
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens
Curtis A Lachowiez, Sanam Loghavi, Tapan M Kadia, et al.
The Lancet. Haematology
|
August 18, 2018
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial
Tapan M Kadia, Jorge Cortes, Farhad Ravandi, et al.
Haematologica
|
May 2, 2024
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse
Alex Bataller, Hagop Kantarjian, Alexandre Bazinet, et al.
American Journal of Hematology
|
November 15, 2017
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms
Rita Assi, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
American Journal of Hematology
|
September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission
Nicholas J Short, Walid Macaron, Tapan Kadia, et al.
Blood Cancer Journal
|
May 2, 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML
Musa Yilmaz, Hagop Kantarjian, Nicholas J Short, et al.
The Lancet. Haematology
|
April 28, 2022
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Page
of 44